The range of surgical benign prostatic hyperplasia (BPH) treatments has hugely expanded in recent years. There is a need to keep up-to-date with ongoing innovations in BPH surgery, and critically appraise the new emerging treatments. The aim of this systematic review was to critically analyse the recent evidence for novel BPH therapies, not presently discussed in urological guidelines
Methods:
An initial scoping search was conducted to identify relevant BPH treatments for inclusion: Optilume® BPH, transperineal laser ablation (TPLA), novel implantable nitinol devices, transurethral columnar balloon dilatation (TUCBD) and transurethral ultrasound ablation (TULSA). A systematic review was conducted of these treatments, searching MEDLINE, SCOPUS and PubMed databases, limited to within 5 years.
Results:
A total of 26 independent studies were included: 14 TPLA, 2 Optilume BPH, 2 TULSA, 5 TUCBD and 3 novel nitinol devices (ClearRing, Urocross Expander, Butterfly stent). For TPLA, most studies demonstrated significant improvement in efficacy outcomes in the absence of adverse events, although most trials were of small patient numbers with short follow-up. The highest quality evidence was presented by the randomised sham-controlled PINNACLE study for Optilume BPH, showing sustained significant International Prostate Symptom Score (IPSS) improvements at 2 years, and low retreatment rates. The evidence for TULSA was limited, showing unclear benefit and concerns about cost-effectiveness. The three novel nitinol device studies were of low evidence quality, with a high number of device-related events for the ClearRing and Butterfly implants. The Urocross Expander had a better safety profile, but limited efficacy data. The TUCBD studies showed contradictory outcomes, with possible confounding from combined bladder neck resection.
Conclusion:
This review has identified that TPLA and Optilume BPH appear to have the strongest evidence base and show promise as future BPH treatments. Further higher quality research is required for TULSA, TUCBD and novel nitinol devices.
CornuJNZantekPBurttG, et alMinimally invasive treatments for benign prostatic obstruction: A systematic review and network meta-analysis. Eur Urol2023; 83(6): 534–547.
5.
ShinBNHQuLRheeH, et alSystematic review and network meta-analysis of re-intervention rates of new surgical interventions for benign prostatic hyperplasia. BJU Int2024; 134: 155–165.
6.
van KollenburgRAAvan RielLAMJGde BruinDM, et alNovel minimally invasive treatments for lower urinary tract symptoms: A systematic review and network meta-analysis. Int Braz J Urol2023; 49(4): 411–427.
7.
PageMJMcKenzieJEBossuytPM, et alThe PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
SterneJAHernánMAReevesBC, et alROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016; 355: i4919.
10.
SterneJACSavovićJPageMJ, et alRoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ2019; 366: l4898.
11.
CampbellMMcKenzieJESowdenA, et alSynthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ2020; 368: l6890.
12.
BertoloRIacovelliVCiprianiC, et alEjaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: A randomized trial. BJU Int2023; 132(1): 100–108.
13.
CaiHZhuCFangJ.Ultrasound-guided perineal laser ablation versus prostatic arterial embolization for benign prostatic hyperplasia: Two similar short-term efficacies. Acta Radiol2023; 64(5): 2033–2039.
14.
CaiHJFangJHKongFL, et alUltrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: A new minimally invasive interventional therapy. Acta Radiol2022; 63(4): 553–558.
15.
CanatHLGurbuzCBozkurtM.Transurethral resection of the prostate (TURP) versus transperineal laser ablation (TPLA) due to benign prostatic hyperplasia (BPH): Prospective and comparative study. Int Urol Nephrol2023; 55(11): 2747–2752.
16.
de RienzoGLorussoAMinafraP, et alTransperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Europ Urol2021; 80(1): 95–103.
17.
DestefanisPSibonaMVitielloF, et alTrans – Perineal laser ablation of the prostate in high surgical risk patients affected by severe lower urinary tract symptoms related to benign prostatic obstruction. Prostate Cancer Prostat Dis2023; 27: 693–699.
18.
FregoNSaitaACasaleP, et alFeasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: A single institutional experience. World J Urol2021; 39(10): 3867–3873.
19.
LaganàADi LascioGDi BlasiA, et alUltrasound-guided SoracteLite™ transperineal laser ablation (TPLA) of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH): A prospective single-center experience. World J Urol2023; 41(4): 1157–1162.
20.
ManentiGPerrettaTCalcagniA, et al3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia. Eur Radiol Exp2021; 5(1): 41.
21.
MinafraPDE RienzoGGerbasiS, et alThree years outcomes of transperineal laser ablation of the prostate. Minerva Urol Nephrol2023; 75(4): 471–478.
22.
PacellaCMPatelliGIapiccaG, et alTransperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: A feasibility study. Results at 6 and 12 months from a retrospective multi-centric study. Prostate Cancer Prostatic Dis2020; 23(2): 356–363.
23.
PolverinoPLo ReMSaladinoM, et alCould transperineal interstitial laser ablation of the prostate be the right option for highly-comorbid patients with lower urinary tract symptoms due to benign prostatic obstruction? A preliminary single-center experience focusing on functional and safety outcomes. Minerva Urol Nephrol2023; 13: 13.
24.
SessaFPolverinoPBisegnaC, et alTransperineal laser ablation of the prostate with EchoLaser™ system: Perioperative and short-term functional and sexual outcomes. Front Urol2022; 2: 969208.
25.
van KollenburgRvan RielLBloemenP, et alTransperineal laser ablation as treatment for benign prostatic obstruction: Safety, feasibility and functional outcomes-A pilot study. BJUI Compass2023; 5(1): 52–59.
26.
KaplanSAMossJFreedmanS, et alThe PINNACLE study: A double-blind, randomized, sham-controlled study evaluating the optilume BPH catheter system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol2023; 210(3): 500–509.
27.
KaplanSAMossJLFreedmanSJ.Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study). Prostate Cancer Prostatic Dis2024; 27(3): 531–536.
28.
KaplanSAPichardoMRijoE, et alOne-year outcomes after treatment with a drug-coated balloon catheter system for lower urinary tract symptoms related to benign prostatic hyperplasia. Prostate Cancer Prostatic Dis2021; 24(4): 1073–1079.
29.
KaplanSAPichardoMRijoE, et alLong-term outcomes after treatment with Optilume BPH: four-year results from the EVEREST study. Can Urol Assoc J2024; 18(11): E319–E325.
30.
PichardoMRijoEEspinoG, et alDurable benefit after treatment of obstructive benign prostatic hyperplasia with a novel drug-device combination product: 2-year outcomes from the EVEREST-I study. World J Urol2023; 41(8): 2209–2215.
31.
MäkeläPAnttinenMWrightC, et alEvolution of non-perfused volume after transurethral ultrasound ablation of prostate: a retrospective 12-month analysis. Eur J Radiol Open2023; 11: 100506.
32.
ViitalaAAnttinenMWrightC, et alMagnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study. BJU Int2022; 129(2): 208–216.
33.
FangDYangYLiH, et alA retrospective multi-center study of the clinical effects of transurethral columnar balloon dilation of the prostate in the treatment of elderly patients with benign prostatic hyperplasia. Arch Esp Urol2022; 75(10): 844–848.
34.
WangBZhangSSunC, et alComparison between a transurethral prostate split and transurethral prostate resection for benign prostatic hyperplasia treatment in a small prostate volume: A prospective controlled study. Ann Transl Med2020; 8(16): 1016.
35.
ZhangDPPanZBZhangHT.Urinary and sexual function changes in benign prostatic hyperplasia patients before and after transurethral columnar balloon dilatation of the prostate. World J Clin Cases2022; 10(20): 6794–6802.
36.
ZhangMJiaJMengQ, et alClinical application of directional dilation in transurethral columnar balloon dilation of the prostate. Pak J Med Sci2022; 38(6): 1489–1494.
37.
ZhouGHeJHuangG, et alEfficacy and safety of transurethral columnar balloon dilation of the prostate for the treatment of benign prostatic hyperplasia: A multicenter trial. Comput Math Methods Med2022; 2022: 7881247.
38.
KatzRAhmedMSASafadiA, et alThe butterfly: A novel minimally invasive transurethral retraction device for benign hypertrophy of the prostate. Urologia Internationalis2023; 107(4): 406–412.
39.
VjatersENitsanDMulleradM, et alFirst-in-man safety and efficacy of the ClearRing implant for the treatment of benign prostatic hyperplasia. Eur Urol Focus2020; 6(1): 131–136.
40.
WooHHHuangCPHuangWJ, et alThe EXPANDER-1 trial: Introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Prostate Cancer Prostatic Dis2022; 25(3): 576–582.
41.
DindoDDemartinesNClavienPA.Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg2004; 240(2): 205–213.
LopateguiDMPortoJGBhatiaA, et alLetter Re: ‘Ejaculatory function following transperineal laser ablation vs TURP for benign prostatic obstruction: A randomized trial’. BJU Int2024; 133(5): 628.
48.
CocciAPezzoliMBiancoF, et alTransperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: the results of a Delphi consensus project. Asian J Urol2024; 11(2): 271–279.
49.
SessaFPolverinoPSienaG, et alTransperineal Laser Ablation of the Prostate (TPLA) for lower urinary tract symptoms due to benign prostatic obstruction. J Clin Med2023; 12(3): 1860.
50.
TafuriAPanunzioADe CarloF, et alTransperineal laser ablation for benign prostatic enlargement: A systematic review and pooled analysis of pilot studies. J Clin Med2023; 12(5): 1860.
51.
TzelvesLNagasubramanianSPinitasA, et alTransperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: A systematic review of existing literature. Ther Adv Urol2023; 15: 17562872231198634.
52.
KaplanSA.MP27-08 Interim 5-year outcomes after treatment with a novel minimally invasive drug/device product. J Urol2024; 211(55): e426.
53.
McVaryKTGangeSNShoreND, et alTreatment of LUTS secondary to BPH while preserving sexual function: Randomized controlled study of prostatic urethral lift. J Sexual Med2014; 11(1): 279–287.
54.
McVaryKTRogersTRoehrbornCG.Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology2019; 126: 171–179.
55.
EureGRukstalisDRoehrbornC.Prostatic urethral lift for obstructive median lobes: Consistent results across controlled trial and real-world settings. J Endourol2023; 37(1): 50–59.
56.
ChughtaiBEltermanDShoreN, et alThe iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A multicenter, randomized, controlled trial. Urology2021; 153: 270–276.
57.
IliPSariFBucakMN, et alDNA damaging effect of paclitaxel in the epididymal sperms as a chemotherapeutic agent and possible remedies to prevent this effect: A study on reproductive potential of male cancer patients of reproductive age. Theriogenology2019; 132: 201–211.
NIHR. Prostate Resection versus Minimally Invasive Surgery Evaluation Trial- PREMISE trial: National Institute for Health and Care Research, 2022, https://fundingawards.nihr.ac.uk/award/NIHR131984
